Novo Nordisk's Oral Ambitions Face a Formidable Rival and Fiscal Headwinds

Novo Nordisk touts superior weight loss & tolerability for its oral Wegovy pill vs Lilly's Foundayo, while launching a high-dose injectable and facing financial headwinds.

Novo Nordisk is fighting to defend its lucrative obesity drug franchise on multiple fronts. As competitor Eli Lilly launches its own oral treatment, the Danish pharmaceutical giant is highlighting clinical data it claims shows superior patient outcomes. Yet this medical offensive is set against a backdrop of significant financial pressure and a stock price languishing near yearly lows.

The company presented findings from its ORION study at a recent medical conference, employing an indirect comparison to Lilly's newly approved drug, Foundayo (orforglipron). The analysis suggests Novo's oral Wegovy pill achieves approximately a three-percentage-point greater weight loss. More strikingly, it indicates the risk of patients discontinuing Lilly's treatment due to side effects is about 14 times higher, with gastrointestinal issues being a primary concern. In a separate assessment, 84% of respondents preferred the side-effect profile of Novo's semaglutid.

This push comes as Lilly's Foundayo, which received accelerated FDA approval on April 2, offers a practical advantage: it can be taken without a fasting period. Novo's oral semaglutid requires patients to fast for 30 minutes prior to ingestion. Novo Nordisk asserts its drug demonstrates "significantly higher mean weight loss," though this claim is based on previously published studies rather than new head-to-head data.

Beyond the pill-versus-pill battle, Novo is expanding its injectable portfolio. On April 7, it launched Wegovy HD, the highest available injection dose containing 7.2 mg of semaglutid. Data from the STEP-UP study showed an average weight loss of about 21% after 72 weeks. This high-dose variant is designed to close the gap with Lilly's Zepbound, which currently commands over 60% of the US obesity drug market.

A critical, longer-term opportunity for Novo lies in tapping a new patient pool. Analysts estimate up to a quarter of US adults suffer from needle phobia, a group that has historically avoided GLP-1 injectable therapies. The oral Wegovy pill is attracting these first-time users rather than cannibalizing existing injectable patients. Within three months of launch, the pill generated tens of thousands of new prescriptions. A GlobalData analysis from March projects the total Wegovy portfolio will grow from $13.5 billion in 2026 to $18.9 billion by 2031, with the pill alone contributing $2.76 billion.

However, the company's financial outlook is clouded. For 2026, Novo Nordisk anticipates adjusted sales growth of between minus 5% and minus 13% at constant exchange rates. This forecast is pressured by a Most-Favored-Nations pricing agreement with the US government, reduced Medicaid reimbursements, and ongoing price competition in the US market. Further challenges include generic competition in India, where the semaglutid patent recently expired.

The stock reflects these pressures, having lost nearly 28% since the start of the year and trading just above its 52-week low at a recent price of EUR 32.20. In March, Bernstein rated the shares "Underperform," warning of a persistent earnings revision cycle.

Investors are now looking ahead to a key regulatory catalyst. The US FDA is expected to decide on Novo's next-generation drug, CagriSema—a combination of cagrilintide and semaglutid—around the turn of the year 2026/2027. Phase 3 data (REDEFINE 1) after 68 weeks showed average weight losses of 22.7% for CagriSema, compared to 16.0% for semaglutid alone and 1.8% for a placebo. This decision is seen as a pivotal binary event that could shift market sentiment ahead of the company's Capital Markets Day in September 2026.

The immediate commercial test will be the prescription trends for Lilly's Foundayo. The coming months will reveal whether Novo Nordisk's touted advantages in efficacy and tolerability are enough to defend its market share against a formidable and newly armed rival.